PD-1 inhibitor

Phase 3Small molecule

PD-1 inhibitor is one of 543 small molecule programs targeting Gastroesophageal Junction Adenocarcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

542

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gastroesophageal Junction AdenocarcinomaActive, not recruiting

Esophageal Squamous Cell CarcinomaActive, not recruiting

Nasopharyngeal CarcinomaActive, not recruiting

Esophageal CancerActive, not recruiting

LymphomaActive, not recruiting

AdenocarcinomaActive, not recruiting

ChondrosarcomaActive, not recruiting

Chronic HepatitisActive, not recruiting

Triple-Negative Breast CancerActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Gastroesophageal Junction AdenocarcinomaPhase 1/Phase 2

Active, not recruiting

Esophageal Squamous Cell CarcinomaPhase 2

Active, not recruiting

Nasopharyngeal CarcinomaPhase 2

Active, not recruiting

Esophageal CancerPhase 1

Active, not recruiting

LymphomaPhase 2

Active, not recruiting

AdenocarcinomaPhase 3

Active, not recruiting

ChondrosarcomaPhase 2

Active, not recruiting

Chronic HepatitisPhase 2

Active, not recruiting

Triple-Negative Breast CancerPreclinical

Active, not recruiting

Non-Small Cell Lung CancerPreclinical

Active, not recruiting

Showing 10 of 22 indications

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

PD-1 inhibitor

Johnson & Johnson

Phase 3

2 2

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 3

Zofran

Novartis

Preclinical

2 4

Tafasitamab

Incyte

Preclinical

7 5

Nuvigil

NNuvo Research GmbH

Preclinical

1 6

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 7

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 8

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Systemic Therapy

1 10

PEG-Intron

Merck & Co.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Recruiting

Non-Small Cell Lung Cancer

NCT05486650

Q4 2026

Phase 1Recruiting

Patients With Advanced Solid Tumors

NCT05916248

Q1 2027

Phase 2Recruiting

Nasopharyngeal Carcinoma

NCT05290194

N/ARecruiting

First-Line Treatment

NCT06752044

N/ARecruiting

First-Line Treatment

NCT06752057

Q2 2027

Phase 1Active, not recruiting

Relapsed/refractory Multiple Myeloma

NCT05338775

Clinical

Trials by Indication[1]

Maintenance Therapy3 trials

ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and ASCT

Not yet recruiting·RRuijin Hospital·Phase 2·NCT06646666·35 enrolled

PD1 and PARP for Maintenance Therapy in NSLLC

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT05392686·52 enrolled

CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC

Recruiting·FFudan University·Phase 3·NCT06964568·452 enrolled

Esophageal Cancer3 trials

Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy

Recruiting·—·Phase 2·NCT06084897·120 enrolled

PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer

Recruiting·—·Phase 3·NCT06086457·436 enrolled

Endostatin Adenovirus With Checkpoint Inhibitor in Advanced Head and Neck or Esophageal Cancer

Not yet recruiting·SSichuan University·Phase 1·NCT07154108·40 enrolled

Safety and Efficacy3 trials

CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC

Completed·BBioAtla, Inc.·Phase 2·NCT04681131·85 enrolled

Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC

Unknown status·HHunan Cancer Hospital·Phase 2·NCT03994744·68 enrolled

CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma

Completed·BBioAtla, Inc.·Phase 1/2·NCT03425279·245 enrolled

Gastroesophageal Junction Adenocarcinoma3 trials

Hypofractionated Radiotherapy Combined With Immunochemotherapy for Conversion Treatment of Gastroesophageal Junction Adenocarcinoma

Recruiting·WWest China Hospital·Phase 1/2·NCT07072351·88 enrolled

Hypofractionated Radiotherapy Plus Immunochemotherapy for Neoadjuvant Treatment of Gastroesophageal Junction Adenocarcinoma

Recruiting·WWest China Hospital·Phase 1/2·NCT07182565·84 enrolled

Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma

Recruiting·BBeijing Biostar Pharmaceuticals Co., Ltd.·Phase 2/3·NCT06841679·778 enrolled

Gastric Cancer3 trials

Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer

Not yet recruiting·JJinbo Yue·Phase 2·NCT07007182·54 enrolled

Neoadjuvant Toripalimab for dMMR/MSI-H Gastric Cancer

Unknown status·SSun Yat-sen University·Phase 2·NCT05994456·24 enrolled

CT and MRI in Prediction of Response in Patients With Gastric Cancer Following Neoadjuvant Chemotherapy and/or Immunotherapy

Unknown status·TThe First Hospital of Jilin University··NCT04913896·200 enrolled

36 more indications

Non-Small Cell Lung Cancer2 trials

An Observational Clinical Study of Stereotactic Radiotherapy for Advanced Non-Small Cell Lung Cancer With Stable Disease After PD-1 Inhibitor Treatment

Recruiting·XXinqiao Hospital of Chongqing··NCT05486650·20 enrolled

Neoadjuvant Immunotherapy With Chemotherapy for Stage I-IIIB Non-Small Cell Lung Cancer Patients

Unknown status·PPeking Union Medical College·Phase 2·NCT04941417·60 enrolled

Lymphoma2 trials

PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma

Unknown status·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT05137886·47 enrolled

The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study

Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT07240194·24 enrolled

Clinical Trial2 trials

Transarterial Infusion of PD-1 Antibody Plus TACE-HAIC for Unresectable HCC: a Single-arm, Phase 2 Clinical Trial

Unknown status·SSun Yat-sen University·Phase 2·NCT04814030·80 enrolled

PD-1 Antibody and Lenvatinib Plus TACE-HAIC for Potential Resectable HCC: a Single-arm, Phase 2 Clinical Trial

Unknown status·SSun Yat-sen University·Phase 2·NCT04814043·57 enrolled

Hepatocellular Carcinoma2 trials

Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma

Unknown status·PPeking Union Medical College Hospital·Phase 2·NCT05048017·20 enrolled

TACE Combined With Anti-PD-1 Antibody in Patients With Advanced Hepatocellular Carcinoma: Study on Efficacy and Immune Microenvironment

Recruiting·FFudan University··NCT07100405·50 enrolled

PD-1 Inhibitor2 trials

TIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTT

Recruiting·SSun Yat-sen University·N/A·NCT06622031·42 enrolled

A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC

Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07432568·30 enrolled

Unknown status·SSungkyunkwan University··NCT04115410·4,724 enrolled

Triple-Negative Breast Cancer1 trial

Observational Study on the Sensitivity of Neoadjuvant Immunotherapy in Early Triple-Negative Breast Cancer

Not yet recruiting·SShandong University··NCT06448169·200 enrolled

Refractory Hepatoblastoma1 trial

Sequential PD-1/PD-L1 Inhibitor and LENvatinib in TLCT and Refractory Hepatoblastoma After Chemotherapy

Unknown status·RRenJi Hospital·Phase 2/3·NCT05322187·15 enrolled

PD-1 Inhibitors1 trial

Single-center, Prospective Cohort Study of PD-1 Inhibitors on Clinical Outcomes of Carotid Plaques in Tumor Patients

Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University··NCT05549336·100 enrolled

Melanoma1 trial

CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)

Completed·BBioAtla, Inc.·Phase 1/2·NCT03504488·132 enrolled

Renal Cell Carcinoma1 trial

Application Circulating Tumor DNA Dynamic Monitoring in Clinical Treatment of Metastatic Renal Cell Carcinoma

Unknown status·RRenJi Hospital·N/A·NCT05816642·500 enrolled

Efficacy and Safety1 trial

Real-world Study of Efficacy and Safety of ICIs and TKIs Therapy for HCC

Unknown status·TTongji Hospital··NCT05420922·2,000 enrolled

Adenocarcinoma1 trial

Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma

Recruiting·FFudan University·Phase 3·NCT04997837·433 enrolled

Metastatic Tumors1 trial

First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors

Completed· AbbVie logo

AbbVie·Phase 1·NCT04417465·101 enrolled

R/R B-NHL1 trial

A Combination Study of CAR-T Therapy in r/r B-NHL

Unknown status·RRuijin Hospital·Phase 2·NCT05871684·48 enrolled

Chondrosarcoma1 trial

A Study of Anlotinib Combined With or Without PD-1 Antibody on Unresectable High-grade Chondrosarcoma

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT05193188·70 enrolled

Atherosclerotic Plaque1 trial

Multi-center Observational Study on the Progression of Atherosclerotic Plaques in Anti-PD-1 mAb Treated Tumor Patients by Artery Ultrasound Follow-up

Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University··NCT04922541·50 enrolled

Immune Checkpoint Inhibitors1 trial

Clinical Research on the Use of Immune Checkpoint Inhibitors Combined With Chidamide for the Functional Cure of AIDS

Not yet recruiting·JJun Chen, MD·N/A·NCT06902038·33 enrolled

Squamous Carcinoma1 trial

Chemoradiotherapy Combined With or Without PD-1 Blockade in Anal Canal Squamous Carcinoma Patients

Unknown status·SSixth Affiliated Hospital, Sun Yat-sen University·Phase 3·NCT05374252·102 enrolled

Pancreatic Cancer1 trial

Clinical Study of mRNA Vaccine Combined With PD-1 Inhibitor as Adjuvant Therapy for Postoperative Pancreatic Cancer

Recruiting·RRuijin Hospital·Phase 1·NCT06496373·20 enrolled

Immunochemotherapy1 trial

PROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLC

Recruiting·SSun Yat-sen University·Phase 2·NCT06977074·83 enrolled

Head and Neck Squamous Cell Carcinoma1 trial

Clinical Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy for Operable Locally Advanced Head and Neck Squamous Cell Carcinoma

Unknown status·HHunan Cancer Hospital·Phase 2·NCT04922450·53 enrolled

Esophageal Squamous Cell Carcinoma1 trial

PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Subjects With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

Unknown status·FFujian Cancer Hospital·Phase 2·NCT05007145·92 enrolled

Patients With Advanced Solid Tumors1 trial

Combination Therapy of Personalized mRNA-0217 Vaccines and Pembrolizumab in Patients With Advanced Solid Tumors

Recruiting·RRuijin Hospital·Phase 1·NCT05916248·34 enrolled

Acute Myeloid Leukemia1 trial

XP-005 Personalized Vaccine Alone or in Combination With Toripalimab for the Prevention of Relapse After Remission in Acute Myeloid Leukemia

Recruiting·SShanghai Jiao Tong University School of Medicine·Phase 1·NCT06980155·60 enrolled

Effectiveness1 trial

A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

Active, not recruiting· GSK logo

GSK·Phase 1/2·NCT06710847·14 enrolled

Urothelial Carcinoma1 trial

A Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin Combined With PD-1 Inhibitor and Radiotherapy as Bladder-preserving Therapy in Patients With Localized HER2-high Expressing Muscle-invasive Bladder Urothelial Carcinoma Following Maximal Transurethral Resection

Not yet recruiting·RRenJi Hospital·Phase 2·NCT07142200·45 enrolled

Advanced Refractory Solid Tumors1 trial

Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0)

Unknown status·SSecond Affiliated Hospital of Soochow University·Phase 2·NCT04892498·66 enrolled

Relapsed/Refractory1 trial

PD-1 Inhibitor or PD-1 Inhibitor Plus GVD for Relapsed/Refractory CHL

Unknown status·SSun Yat-sen University·Phase 2·NCT04624984·42 enrolled

Soft Tissue Sarcoma1 trial

Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer

Unknown status·HHunan Cancer Hospital·Phase 2·NCT04239443·120 enrolled

Chronic Hepatitis1 trial

An Efficacy and Safety Study of a Combination of JNJ-73763989, Nucleos(t)Ide Analogs (NA), and a Programmed Cell Death Protein Receptor-1 (PD-1) Inhibitor in Chronic Hepatitis B Participants

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT05275023·37 enrolled

Nasopharyngeal Carcinoma1 trial

Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcinoma

Recruiting·FFifth Affiliated Hospital, Sun Yat-Sen University·Phase 2·NCT05290194·28 enrolled

Locally-advanced Rectal Cancer1 trial

The Therapeutic and Prognostic Implications of Tumor Immune Microenvironment in The Neoadjuvant Immunotherapy Combined With Chemoradiotherapy for Rectal Cancer

Active, not recruiting·PPeking Union Medical College Hospital·Phase 2·NCT05507112·100 enrolled

Relapsed/Refractory Multiple Myeloma1 trial

A Phase 1b Study of Bispecific T Cell Redirection Antibodies in Combination With Checkpoint Inhibition for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT05338775·74 enrolled

Sources

References

[1]
ClinicalTrials.gov — 58 trial records for PD-1 inhibitor. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PD-1 inhibitor compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PD-1 inhibitor. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Johnson & Johnson

PD-1 inhibitor

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q1 2027

Q2 2027

Trials by Indication[1]

Maintenance Therapy3 trials

Esophageal Cancer3 trials

Safety and Efficacy3 trials

Gastroesophageal Junction Adenocarcinoma3 trials

Gastric Cancer3 trials

Non-Small Cell Lung Cancer2 trials

Lymphoma2 trials

Clinical Trial2 trials

Hepatocellular Carcinoma2 trials

PD-1 Inhibitor2 trials

Second-line Treatment2 trials

First-line Treatment2 trials

Immune-related Adverse Events1 trial

Triple-Negative Breast Cancer1 trial

Refractory Hepatoblastoma1 trial

PD-1 Inhibitors1 trial

Melanoma1 trial

Renal Cell Carcinoma1 trial

Efficacy and Safety1 trial

Adenocarcinoma1 trial

Metastatic Tumors1 trial

R/R B-NHL1 trial

Chondrosarcoma1 trial

Atherosclerotic Plaque1 trial

Immune Checkpoint Inhibitors1 trial

Squamous Carcinoma1 trial

Pancreatic Cancer1 trial

Immunochemotherapy1 trial

Head and Neck Squamous Cell Carcinoma1 trial

Esophageal Squamous Cell Carcinoma1 trial

Patients With Advanced Solid Tumors1 trial

Acute Myeloid Leukemia1 trial

Effectiveness1 trial

Urothelial Carcinoma1 trial

Advanced Refractory Solid Tumors1 trial

Relapsed/Refractory1 trial

Soft Tissue Sarcoma1 trial

Chronic Hepatitis1 trial

Nasopharyngeal Carcinoma1 trial

Locally-advanced Rectal Cancer1 trial

Relapsed/Refractory Multiple Myeloma1 trial

References

Drug Info

Quick Facts

Related News